DILOZOL Tablet

Dilozol is indicated in the treatment of acute and chronic intestinal amoebiasis, including the amoebic cyst carries hepatitis, amoebic liver abscess, and other systemic infections caused by E.histolytica and giardiasis.

Dosage and Directions for use

Children: 5-12 years: Half tablet thrice daily for 5 days.

Adults: 1 tablet thrice daily for 5 days. In refractory cases extended treatment for 10 days is recommended.

Hypersensitivity to the components of the formulation.

Contraindicated in children below 5 years of age.

Occasional mild gastrointestinal disturbances: Abdominal pain, distension, nausea, burning sensation in the tongue, headache and dizziness.

Special Precautions:

In elderly patients, the pharmacokinetics of Metronidazole may be altered and monitoring of serum levels may be necessary.

In impaired hepatic function: Patients will severe hepatic disease metabolize Metronidazole slowly, hence dosage adjustments in this category of patients may be required.

(See the package insert about the details below.)

Anticoagulants

Drugs affecting liver enzyme activity (phenytoin, phenobarbital)

The simultaneous administration of drugs that decrease microsomal liver enzyme activity (cimetidine)

Alcohol

Oral contraceptives

The drug should be avoided during pregnancy, particularly during the first trimester.

Since Metronidazole is secreted in breast milk the drug should be avoided during lactation.

Metronidazole is mainly metabolised by hepatic oxidation. Substantial impairment of metronidazole clearance may occur in the presence of advanced hepatic insufficiency. Significant cumulation may occur in patients with hepatic encephalopathy and the resulting high plasma concentrations of metronidazole may contribute to the symptoms of the encephalopathy. Dilozol should therefore, be administered with caution to patients with hepatic encephalopathy.

Dilozol is a combination of metronidazole and diloxanide furoate, useful in the treatment of intestinal and extraintestinal amoebic infections. Diloxanide furoate is a luminal amoebicide actin on the amoebic cyst and trophozite within the lumen of the bowel. Metronidazole is a tissue amoebicide, affecting the parasite in the intestinal wall or other organs. Through its binding to the DNA present inside the cell prevents it from multiplication. Metronidazole is active against a wide range of pathogenic microorganisms notably species of Bacteroide, Fusobacteria, Clostridia, Eubacteria, Anaerobic cocci and Gardnerella vaginalis. It is also active against Trichomonas, Entamoeba histolytica, Giardia lamblia and Balantidium coli.